The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2024 | Assessing NSCLC treatments in under-represented patient populations
Liza Villaruz, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, discusses the findings of a recently published Phase II trial (NCT02879617) testing the safety of durvalumab in historically under-represented subgroups of patients with advanced non-small cell lung cancer (NSCLC). A significant portion of patients with NSCLC have impaired functional capabilities, often leading them to be unable to travel into cities to participate in trials, and the trial is the only study testing the safety and efficacy of durvalumab in patients with NSCLC who have reduced functionality. There are additional studies assessing pembrolizumab and atezolizimab in these under-represented groups. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
